Medizinische Universität Wien
Welcome,         Profile    Billing    Logout  
 81 Trials 
115 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chen, Chunxiao
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
01/25
12/26
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Recruiting
3
408
RoW
Vedolizumab IV, Placebo
Takeda
Crohn's Disease
03/30
05/31
NCT03977480: Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis

Terminated
2
70
RoW
Hemay007, Placebo
Tianjin Hemay Pharmaceutical Co., Ltd
Ulcerative Colitis
08/22
08/22
NCT05770609: A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Recruiting
2
108
RoW
SPH3127 Tablets with Dose A, SPH3127 Tablets with Dose B, SPH3127 Tablets placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Mild to Moderate Ulcerative Colitis
02/25
02/25
Investigator, Madrigal
MAESTRO-NASH, NCT03900429 / 2018-004012-22: A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

Active, not recruiting
3
1759
Europe, Canada, US, RoW
MGL-3196, Resmetirom, Placebo, Liver Biopsy
Madrigal Pharmaceuticals, Inc.
NASH - Nonalcoholic Steatohepatitis
01/28
01/28
NCT04951219: A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Recruiting
3
1000
US
Resmetirom, MGL-3196
Madrigal Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease
03/26
04/26
NCT04643795: Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Completed
1
87
US
MGL-3196
Madrigal Pharmaceuticals, Inc.
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
08/21
08/21
YOUNSI, Mohamed-Salem
BIO|STREAM HF, NCT03366545: Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices

Recruiting
N/A
3000
Europe, Japan, RoW
Cardiac Resynchronization Therapy (CRT)
Biotronik SE & Co. KG
Heart Failure
12/24
06/25
Rieber, Alyssa G
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Pfeiler, Georg Wolfgang
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Bengi, Goksel
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
01/25
12/26
Gleixner, Karoline
LUSPLUS, NCT05181592: Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

Recruiting
3
70
Europe
Luspatercept, Reblozyl
GWT-TUD GmbH, Celgene
Myelodysplastic Syndromes
12/24
06/25
Albinni, Sulaimi
NCT06350032: Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH

Not yet recruiting
3
20
Europe
preservative-free parenteral treprostinil
AOP Orphan Pharmaceuticals AG
Pulmonary Arterial Hypertension
11/28
11/28
 

Download Options